Download MPA Spring Convention 2017 Edited

2017 Maine Pharmacy Association Spring Convention
Pharmacy Law Update
Husson University
April 1, 2017
Greg Cameron, R.Ph
(NO APRIL FOOLS)
1
G. Cameron 2017
2017 Maine Pharmacy Association Spring Convention
• Dental Hygienists and Fluoride Dispensing
• Opioid Law and Regulations Update
• Drug Quality and Security Act 2013
• Comprehensive Addiction & Recovery Act 2016
• Technician & Intern Duties
• Recent Board of Pharmacy Actions
2
OBJECTIVES
G. Cameron 2017
2017 Maine Pharmacy Association Spring Convention
• Public Law 114–198, 114th Congress
• Comprehensive Addiction and Recovery Act of 2016
• (696 PAGES)
• REASON:
 To authorize the Attorney General and Secretary of Health
and Human Services to award grants to address the
prescription opioid abuse and heroin use crisis, and for
other purposes
3
• Comprehensive Addiction and Recovery Act of 2016
G. Cameron 2017
2017 Maine Pharmacy Association Spring Convention
• Parts of this LAW:
TITLE I—PREVENTION AND EDUCATION
TITLE II—LAW ENFORCEMENT AND TREATMENT
TITLE III—TREATMENT AND RECOVERY
TITLE IV—ADDRESSING COLLATERAL CONSEQUENCES
TITLE V—ADDICTION AND TREATMENT SERVICES FOR WOMEN,
FAMILIES, AND VETERANS
 TITLE VI—INCENTIVIZING STATE COMPREHENSIVE INITIATIVES TO
ADDRESS PRESCRIPTION OPIOID ABUSE
 TITLE VII—MISCELLANEOUS
 Sec. 702. Partial fills of schedule II controlled substances





4
• Comprehensive Addiction and Recovery Act of 2016
G. Cameron 2017
2017 Maine Pharmacy Association Spring Convention
SEC. 702. PARTIAL FILLS OF SCHEDULE II CONTROLLED
SUBSTANCES
1. Partial Fills - A prescription for a controlled substance in
schedule II may be partially filled if—
a) it is not prohibited by State law
b) the prescription is written and filled in accordance with
this title, regulations prescribed by the Attorney General,
and State law
c) the partial fill is requested by the patient or the
practitioner that wrote the prescription; and
d) the total quantity dispensed in all partial fillings does not
exceed the total quantity prescribed
5
G. Cameron 2017
• Comprehensive Addiction and Recovery Act of 2016
2017 Maine Pharmacy Association Spring Convention
SEC. 702. PARTIAL FILLS OF SCHEDULE II CONTROLLED
SUBSTANCES
2. REMAINING PORTIONS.—
a) IN GENERAL.—Except as provided in subparagraph (B), remaining
portions of a partially filled prescription for a controlled substance
in schedule II—
i.
may be filled; and
ii. shall be filled not later than 30 days after the date on which
the prescription is written
b) EMERGENCY SITUATIONS.—In emergency situations, the remaining
portions of a partially filled prescription for a controlled substance
in schedule II—
i.
may be filled; and
ii. shall be filled not later than 72 hours after the prescription is
issued
G. Cameron 2017
• Comprehensive Addiction and Recovery Act of 2016
6
2017 Maine Pharmacy Association Spring Convention
SEC. 702. PARTIAL FILLS OF SCHEDULE II CONTROLLED
SUBSTANCES
3. CURRENTLY LAWFUL PARTIAL FILLS.—
a) Notwithstanding paragraph (1) or (2), in any circumstance in
which, as of the day before the date of enactment of this
subsection, a prescription for a controlled substance in
schedule II may be lawfully partially filled, the Attorney
General may allow such a prescription to be partially filled
7
G. Cameron 2017
• Comprehensive Addiction and Recovery Act of 2016
2017 Maine Pharmacy Association Spring Convention
SEC. 702. PARTIAL FILLS OF SCHEDULE II CONTROLLED
SUBSTANCES
4. RULE OF CONSTRUCTION.—
a) Nothing in this section shall be construed to affect the
authority of the Attorney General to allow a prescription for a
controlled substance in schedule III, IV, or V of section 202(c)
of the Controlled Substances Act (21 U.S.C. 812(c)) to be
partially filled
8
G. Cameron 2017
• Comprehensive Addiction and Recovery Act of 2016
2017 Maine Pharmacy Association Spring Convention
Compounding Quality Act
Title I of the Drug Quality and Security Act of 2013
On November 27, 2013, President Obama signed the
Drug Quality and Security Act (DQSA), legislation that
contains important provisions relating to the oversight
of compounding of human drugs.
9
G. Cameron 2017
Drug Quality and Security Act of 2013 (Compounding Quality Act)
2017 Maine Pharmacy Association Spring Convention
H.R.3204 — 113th Congress (2013-2014)
Public Law No: 113-54 (11/27/2013)
• Drug Quality and Security Act - Title I: Drug
Compounding - Compounding Quality Act
• (Sec. 102) Amends the Federal Food, Drug, and
Cosmetic Act (FFDCA) with respect to the regulation
of compounding drugs
10
G. Cameron 2017
Drug Quality and Security Act of 2013 (Compounding Quality Act)
2017 Maine Pharmacy Association Spring Convention
•
Exempts compounded drugs from:
 new drug requirements
 labeling requirements
 track and trace requirements
• IF, the drug is compounded by or under the direct
supervision of a licensed pharmacist in a registered
outsourcing facility and meets applicable requirements
11
G. Cameron 2017
Drug Quality and Security Act of 2013 (Compounding Quality Act)
2017 Maine Pharmacy Association Spring Convention
G. Cameron 2017
•
Establishes annual registration requirement for any
outsourcing facility
•
Requires a facility to report biannually to the Secretary of
Health and Human Services (HHS) on what drugs are
compounded in the facility and to submit adverse event
reports
•
Subjects such facilities to a risk-based inspection
schedule
Drug Quality and Security Act of 2013 (Compounding Quality Act)
12
2017 Maine Pharmacy Association Spring Convention
• Requires the Secretary to:
 Assess an annual establishment fee on each
outsourcing facility
 A re-inspection fee, as necessary
13
G. Cameron 2017
Drug Quality and Security Act of 2013 (Compounding Quality Act)
2017 Maine Pharmacy Association Spring Convention
• Prohibits the resale of a compounded drug labeled
“not for resale” or the intentional falsification of a
prescription for a compounded drug
• Deems a compounded drug to be misbranded if its
advertising or promotion is false or misleading
14
G. Cameron 2017
Drug Quality and Security Act of 2013 (Compounding Quality Act)
2017 Maine Pharmacy Association Spring Convention
• State Boards of Pharmacy are required to
send reports:
1. Describing any disciplinary actions taken
against compounding pharmacies
2. Any recall of a compounded drug
3. Any concerns that a compounding
pharmacy may be violating the FFDCA
15
G. Cameron 2017
Drug Quality and Security Act of 2013 (Compounding Quality Act)
2017 Maine Pharmacy Association Spring Convention
• Revises compounding pharmacy
requirements:
1. Repeals prohibitions on advertising and
promotion of compounded drugs
2. Repeals the requirement that
prescriptions filled by a compounding
pharmacy be unsolicited
16
G. Cameron 2017
Drug Quality and Security Act of 2013 (Compounding Quality Act)
2017 Maine Pharmacy Association Spring Convention
• LABELING OF DRUGS.
A. LABEL.—The label of the drug includes—
i.
the statement ‘This is a compounded drug.’ or a
reasonable comparable alternative statement (as
specified by the Secretary) that prominently identifies
the drug as a compounded drug
ii. the name, address, and phone number of the
applicable outsourcing facility
17
G. Cameron 2017
Drug Quality and Security Act of 2013 (Compounding Quality Act)
2017 Maine Pharmacy Association Spring Convention
• LABELING OF DRUGS.
A. LABEL.—The label of the drug includes—
iii. with respect to the drug—
1) the lot or batch number;
2) the established name of the drug
3) the dosage form and strength
4) the statement of quantity or volume, as appropriate
5) the date that the drug was compounded
6) the expiration date
18
G. Cameron 2017
Drug Quality and Security Act of 2013 (Compounding Quality Act)
2017 Maine Pharmacy Association Spring Convention
• LABELING OF DRUGS.
A. LABEL.—The label of the drug includes—
iii. with respect to the drug— (CONTINUED)
7) storage and handling instructions
8) the National Drug Code number, if available
9) the statement ‘Not for resale’, and
10) if the drug is dispensed or distributed other than
pursuant to a prescription for an individual identified
patient, the statement ‘Office Use Only’
11) a list of active and inactive ingredients, identified by
established name and the quantity or proportion of each
ingredient. (If it doesn’t fit on the label , see container
requirement).
G. Cameron 2017
Drug Quality and Security Act of 2013 (Compounding Quality Act)
19
2017 Maine Pharmacy Association Spring Convention
• Labeling of the CONTAINER—
A. The container from which the individual units of the drug are
removed for dispensing or for administration (such as a plastic
bag containing individual product syringes) shall include—
i.
a list of active and inactive ingredients, identified by
established name and the quantity or proportion of each
ingredient
ii.
information to facilitate adverse event reporting:
www.fda.gov/medwatch and 1–800– FDA–1088
iii. directions for use, including, as appropriate, dosage and
administration
20
G. Cameron 2017
Drug Quality and Security Act of 2013 (Compounding Quality Act)
2017 Maine Pharmacy Association Spring Convention
•
REGISTRATION OF OUTSOURCING FACILITIES
A. ANNUAL REGISTRATION
i.
Upon electing and in order to become an outsourcing
facility, shall register with the Secretary its name, place
of business, a point contact email address, and unique
facility identifier
ii. shall indicate whether the outsourcing facility intends to
compound a drug that appears on the list in effect
under section 506E during the subsequent calendar
year
21
G. Cameron 2017
Drug Quality and Security Act of 2013 (Compounding Quality Act)
2017 Maine Pharmacy Association Spring Convention
•
REGISTRATION OF OUTSOURCING FACILITIES
B. AVAILABILITY OF REGISTRATION FOR INSPECTION LIST
i.
The Secretary shall make available for inspection, to any
person so requesting, any registration filed or facility
registered as an outsourcing facility
ii.
State in which each such facility is located
iii. whether the facility compounds from bulk drug substances,
and
iv. whether any such compounding from bulk drug substances is
for sterile or non-sterile drugs
22
G. Cameron 2017
Drug Quality and Security Act of 2013 (Compounding Quality Act)
2017 Maine Pharmacy Association Spring Convention
•
REGISTRATION OF OUTSOURCING FACILITIES (Continued)
C. DRUG REPORTING BY OUTSOURCING FACILITIES
i.
Report due once during the month of June, and once during the month of
December of each year
a) identifying the drugs compounded during the previous 6-month
period and
ii.
with respect to each drug identified providing the active ingredient, the
source of such active ingredient, the NDC of the source drug or bulk
active ingredient, if available, the strength of the active ingredient per
unit, the dosage form and route of administration, the package
description, the number of individual units produced, and the National
Drug Code number of the final product, if assigned
23
G. Cameron 2017
Drug Quality and Security Act of 2013 (Compounding Quality Act)
2017 Maine Pharmacy Association Spring Convention
•
REGISTRATION OF OUTSOURCING FACILITIES
D. RISK-BASED INSPECTION FREQUENCY
i. Outsourcing facilities
1) shall be subject to inspection
E.
RISK-BASED SCHEDULE.—The Secretary, acting through one or
more officers or employees duly designated shall inspect
outsourcing facilities in accordance with a risk-based schedule
established by the Secretary’
24
G. Cameron 2017
Drug Quality and Security Act of 2013 (Compounding Quality Act)
2017 Maine Pharmacy Association Spring Convention
•
REGISTRATION OF OUTSOURCING FACILITIES
F.
RISK FACTORS.—shall inspect outsourcing facilities according to
the known safety risks of such outsourcing facilities, which shall
be based on the following factors
i. The compliance history of the outsourcing facility
ii.
The record, history, and nature of recalls linked to the
outsourcing facility
iii. The inherent risk of the drugs compounded at the
outsourcing facility
iv. The inspection frequency and history of the outsourcing
facility
v.
Whether the outsourcing facility has registered
25
G. Cameron 2017
Drug Quality and Security Act of 2013 (Compounding Quality Act)
2017 Maine Pharmacy Association Spring Convention
•
REGISTRATION OF OUTSOURCING FACILITIES
G. ADVERSE EVENT REPORTING.—Outsourcing facilities shall
submit adverse event reports to the Secretary
H. INTERIM LIST.— the Secretary may designate drugs,
categories of drugs, or conditions
I.
UPDATES.—The Secretary shall review, and update as
necessary, the regulations containing the lists of drugs,
categories of drugs, or conditions regularly, but not less
than once every 4 years
26
G. Cameron 2017
Drug Quality and Security Act of 2013 (Compounding Quality Act)
2017 Maine Pharmacy Association Spring Convention
•
REGISTRATION OF OUTSOURCING FACILITIES
J.
DEFINITIONS
1) The term ‘compounding’ includes the combining,
admixing, mixing, diluting, pooling, reconstituting, or
otherwise altering of a drug or bulk drug substance to
create a drug
27
G. Cameron 2017
Drug Quality and Security Act of 2013 (Compounding Quality Act)
2017 Maine Pharmacy Association Spring Convention
•
REGISTRATION OF OUTSOURCING FACILITIES
J.
DEFINITIONS
2) The term ‘essentially a copy of an approved drug’ means
i. a drug that is identical or nearly identical to an approved
drug, or a marketed drug
ii. a drug, a component of which is a bulk drug substance
that is a component of an approved drug or a marketed
drug, unless there is a change that produces for an
individual patient a clinical difference, as determined by
the prescribing practitioner, between the compounded
drug and the comparable approved drug
28
G. Cameron 2017
Drug Quality and Security Act of 2013 (Compounding Quality Act)
2017 Maine Pharmacy Association Spring Convention
•
REGISTRATION OF OUTSOURCING FACILITIES
J.
DEFINITIONS
3) The term ‘approved drug’ means a drug that is approved
and does not appear on the list of drugs that have been
withdrawn or removed from the market because such
drugs or components of such drugs have been found to
be unsafe or not effective
29
G. Cameron 2017
Drug Quality and Security Act of 2013 (Compounding Quality Act)
2017 Maine Pharmacy Association Spring Convention
•
REGISTRATION OF OUTSOURCING FACILITIES
J.
DEFINITIONS
4) The term ‘outsourcing facility’ means a facility at one
geographic location or address that—
G. Cameron 2017
a)
is engaged in the compounding of sterile drugs
b)
has elected to register as an outsourcing facility and
c)
complies with all of the requirements of this section
d)
is not required to be a licensed pharmacy
e)
may or may not obtain prescriptions for identified
individual patients
Drug Quality and Security Act of 2013 (Compounding Quality Act)
30
2017 Maine Pharmacy Association Spring Convention
•
REGISTRATION OF OUTSOURCING FACILITIES
K. DEFINITIONS
5) The term ‘sterile drug’ means a drug that is intended for
parenteral administration, an ophthalmic or oral
inhalation drug in aqueous format, or a drug that is
required to be sterile under Federal or State law.’’
31
G. Cameron 2017
Drug Quality and Security Act of 2013 (Compounding Quality Act)
2017 Maine Pharmacy Association Spring Convention
32
G. Cameron 2017
2017 Maine Pharmacy Association Spring Convention
• An Act To Allow Dental Hygienists To Prescribe Fluoride
Dentifrice And Antibacterial Rinse
• Apply topical antimicrobials, excluding antibiotics,
including fluoride, for the purposes of bacterial
reduction, caries control and desensitization in the oral
cavity
• The independent practice dental hygienist shall follow
current manufacturer’s instructions in the use of these
medicaments
33
G. Cameron 2017
Dental Hygienists
2017 Maine Pharmacy Association Spring Convention
• Prescribe, dispense, or administer anticavity
toothpastes or topical gels with 1.1% or LESS sodium
fluoride and oral rinses with 0.05%, 0.2%, 0.44%, or
0.5% sodium fluoride and:
• Prescribe, dispense, or administer chlorhexidine
gluconate oral rinse
34
G. Cameron 2017
Dental Hygienists
2017 Maine Pharmacy Association Spring Convention
Effective 7/1/2017
• Total MMEs are not to exceed 100mg / day unless an exception
• Pharmacists may dispense a lesser quantity than is prescribed if
requested by the patient
 Pharmacist must notify the prescriber within 7 days
 Remaining quantity is void (different then new Federal Law)
• All opioid medications must be prescribed electronically, or prescribers
must request a waiver from DHHS
35
G. Cameron 2017
Opiate Law Update LD 1646
2017 Maine Pharmacy Association Spring Convention
•
PMP for the pharmacists (when to check)
o Applies to Opioids and Benzodiazepines
 Patient is not a Maine Resident
 Rx is written by an out of state prescriber
 Patient has not received a prescription for Opioids or
Benzodiazepine within the previous 12 months
 Patient pays cash when the actually have insurance
 Pharmacists may be fined $250 per violation / $5,000
per year for failure to report to the PMP
36
G. Cameron 2017
Opiate Law Update LD 1646
2017 Maine Pharmacy Association Spring Convention
•
PMP Dispensers Must Review:
 # of pharmacies filling controlled substances for this
patient
 # of prescribers prescribing controlled substances for this
patient
 Aggregate MME
 Notify the PMP Office Coordinator and decline filling the
prescription until you can contact the prescriber if you
suspect the prescription is fraudulent or may be
duplication of therapy
37
G. Cameron 2017
Opiate Law Update LD 1646
2017 Maine Pharmacy Association Spring Convention
• Days Supply
o Indication of acute pain
 7 days
o Indication of chronic pain
 30 days
• Early Refills
38
G. Cameron 2017
Opiate Law Update LD 1646
2017 Maine Pharmacy Association Spring Convention
Regulations
•
Definitions
a) Acute Pain – pain that is the normal, predicted physiological
response to noxious chemical, thermal, or mechanical stimulus.
This pain is typically associated with invasive procedures, trauma,
and disease and is usually time-limited
b) Chronic Pain – pain that persists beyond the usual course of an
acute disease or healing and may not be associated with an acute
or chronic pathologic process that causes continuous or
intermittent pain over months or years
39
G. Cameron 2017
Opiate Law Update LD 1646
2017 Maine Pharmacy Association Spring Convention
Code
Exemption
A
Pain associated with active and aftercare cancer treatment. Providers must document in the
medical record that pain is directly related to cancer or cancer treatment. An exemption for
aftercare may be claimed up to 6 months post-remission
B
Palliative care in conjunction with serious illness
C
End-of-life and hospice care
D
Medication assisted treatment for SUD
E
Pregnant individual with pre-existing prescription for >100MMEs (only applies during
pregnancy
F
Acute pain for the patient with pre-existing opioid prescription for chronic pain. The acute
pain must be new or onset or postoperative, 7day limit applies
G
Individuals pursuing an active taper of opioid medications with a maximum taper period of 6
months after which the opioid limitations will apply unless the patient meets additional
exceptions
40
G. Cameron 2017
Opiate Law Update LD 1646
2017 Maine Pharmacy Association Spring Convention
• Diagnosis code:
 ICD-10 code must be included on any (aggregate)
prescription that exceeds 100 MMEs
 Not required on veterinary prescriptions
• Exemption code:
 Must be included if claiming exemption from the 100
MME aggregate daily limit
41
G. Cameron 2017
Opiate Law Update LD 1646
2017 Maine Pharmacy Association Spring Convention
• Requirement that Dispensers Report Information to the PMP by
Electronic Means
• No later than the close of business on the next business day after
dispensing a controlled substance, dispensers must report:
Dispenser identification number
Dates prescription was filled and delivered (issued)
Prescription number
Whether the prescription is new or a refill
National drug code (NDC) of the drug dispensed
Quantity dispensed, Dosage
Patient ID number, name, address, and date of birth
Date prescription was issued by the prescriber
Exemption code and ICD-10 code if aggregate >100 MMEs
If prescription is for animal use
G. Cameron 2017
Opiate Law Update LD 1646
42
2017 Maine Pharmacy Association Spring Convention
Calculating Total Daily Dose of Opioids For Safer Dosage - CDC
https://www.cdc.gov/drugoverdose/pdf/calculating_total_da
ily_dose-a.pdf
Opioid Comparison Table
http://www.agencymeddirectors.wa.gov/Calculator/DoseCalc
ulator.htm
43
G. Cameron 2017
Opiate Law Update LD 1646
2017 Maine Pharmacy Association Spring Convention
§13834. Prohibited acts
1. Delegate authority. A pharmacist may not delegate the pharmacist's authority
to administer drugs or vaccines; except that a pharmacist licensed under this chapter
who has obtained a certificate of administration pursuant to section 13832 may
delegate the authority to administer drugs and vaccines to a pharmacy intern
who is under that pharmacist's direct supervision and who has obtained drug
administration training pursuant to section 13832, subsection 3. A pharmacy intern
may administer drugs and vaccines only to a person 18 years of age or older.
[ 2013, c. 98, §1 (AMD) .]
44
G. Cameron 2017
Pharmacy Technicians & Pharmacy Interns
2017 Maine Pharmacy Association Spring Convention
•
Pharmacy Technicians - A pharmacy technician or pharmacy
intern working under the direct supervision of a pharmacist may:
1. Accept delivery of prescription medication to be loaded into
a dispensing machine at a point of care location
2. Stock a dispensing machine at a point of care location
3. Remove drugs from a dispensing machine at a point of care
location for quality assurance purposes or to carry out a
change in formulary; and
4. Perform other functions related to an automated pharmacy
system except for the removal of drugs from a dispensing
machine at a point of care location for purposes of
administration or dispensing to patients.
G. Cameron 2017
Pharmacy Technicians & Pharmacy Interns
45
2017 Maine Pharmacy Association Spring Convention
•
No person with access to a dispensing machine may remove more
drugs than necessary to fill a prescription or meet the immediate
needs of a patient in a hospital or institution.
46
G. Cameron 2017
Pharmacy Technicians & Pharmacy Interns
2017 Maine Pharmacy Association Spring Convention
• Telephone Prescription Drug Orders
 A pharmacist or pharmacy intern may accept an original or
renewal prescription drug order telephoned to a pharmacy by a
practitioner or authorized agent of the practitioner
 A pharmacy technician may accept an original or renewal
prescription drug order telephoned to a pharmacy by a
practitioner or authorized agent of the practitioner to the extent
authorized by the pharmacist on duty.
• Facsimile Prescription Drug Orders
 A pharmacist, pharmacy intern or pharmacy technician may
accept a prescription drug order transmitted by facsimile
machine or facsimile computer software directly to a pharmacy.
47
G. Cameron 2017
Pharmacy Technicians & Pharmacy Interns
2017 Maine Pharmacy Association Spring Convention
• Generally
+ The pharmacist in charge or the pharmacy shall determine the
duties of pharmacy technicians based upon the needs of the
pharmacy
+ Pharmacy technicians are limited to performing tasks in the
dispensing of prescription legend drugs and nonjudgmental
support services
• Automated Pharmacy Systems
+ A pharmacy technician on duty at an institutional pharmacy may
perform the duties relating to an automated pharmacy system
under the direct supervision of a pharmacist
48
G. Cameron 2017
Pharmacy Technicians & Pharmacy Interns
2017 Maine Pharmacy Association Spring Convention
• Limitations
 A pharmacy technician may not perform any of the following tasks:
+ Clinically evaluate a patient profile relative to drugs that have
or will be dispensed;
+ Perform patient counseling;
+ Make decisions that require the education and professional
training of a pharmacist; or
+ Sign any federally-required controlled substance or inventory
form
49
G. Cameron 2017
Pharmacy Technicians & Pharmacy Interns
2017 Maine Pharmacy Association Spring Convention
• Verification of Status
 The pharmacist in charge shall ensure that each pharmacy
technician employed at the pharmacy for which the pharmacist in
charge is responsible is licensed with the board
 A pharmacy technician shall carry the wallet-sized license card
issued by the board at all times the technician is on duty and shall
produce the card upon request of the pharmacist in charge, a
pharmacist on duty or an agent of the board
 No pharmacist in charge or pharmacist on duty shall permit a
person who is not licensed pursuant to the terms of this chapter
to perform the duties of a pharmacy technician
50
G. Cameron 2017
Pharmacy Technicians & Pharmacy Interns
2017 Maine Pharmacy Association Spring Convention
• Notice of Employment and Non-Employment of
Pharmacy Technicians
 The pharmacist in charge shall notify the board via letter, fax,
email or on line within 10 days after the commencement or
cessation of employment of any pharmacy technician at a
pharmacy for which the pharmacist in charge is responsible
51
G. Cameron 2017
Pharmacy Technicians & Pharmacy Interns
2017 Maine Pharmacy Association Spring Convention
• Notice of Termination of Employment For Drug-Related
Reasons or Theft
 The pharmacist in charge or a designee of the pharmacist in charge shall
notify the board via letter, fax, email or on line of the termination of
employment of a pharmacy technician for any of the following reasons
and shall include in the notice the reason for the termination. Notice
shall be provided within 7 days after the termination
 Any drug-related reason, including but not limited to adulteration, abuse,
theft or diversion;
 Theft of non-drug merchandise; or
 Theft of cash or credit/debit card data.
52
G. Cameron 2017
Pharmacy Technicians & Pharmacy Interns
2017 Maine Pharmacy Association Spring Convention
Discipline
• Pharmacy technicians are subject to the disciplinary provisions of 10
MRSA §8003(5-A), 32 MRSA §§ 13742-A and 13743 and Chapters 30,
31 and 32 of the board's rules.
53
G. Cameron 2017
Pharmacy Technicians & Pharmacy Interns